Search
Adagrasib
go.drugbank.com/drugs/DB15568ApprovedInvestigational[A254052] In a phase I/IB clinical study that included patients with KRAS<sup>G12C</sup>-mutated advanced solid tumors (NCT03785249), adagrasib exhibited anti-tumor activity. … KRAS mutations are highly common in cancer and account for approximately 85% of all RAS family mutations.
Amsacrine
go.drugbank.com/drugs/DB00276ApprovedInvestigationalWithdrawnIt is effective in the treatment of acute leukemias and malignant lymphomas, but has poor activity in the treatment of solid tumors. … It is frequently used in combination with other antineoplastic agents in chemotherapy protocols. It produces consistent but acceptable myelosuppression and cardiotoxic effects.
Categories: Compounds used in a research, industrial, or household settingProducts: Amlyo 75 mg Pulver für ein Konzentrat zur Herstellung einer Infusionslösung, Amsidyl 75 mg/1,5 ml Konzentrat und Lösungsmittel für ein Konzentrat zur Herstellung einer InfusionslösungFluticasone furoate
go.drugbank.com/drugs/DB08906ApprovedInvestigationalFluticasone furoate is a synthetic glucocorticoid available as an inhaler and nasal spray for various inflammatory indications[FDA Label][F4364]. Fluticasone furoate was first approved in 2007[L5965].
Nitisinone
go.drugbank.com/drugs/DB00348ApprovedNitisinone is a synthetic reversible inhibitor of 4-hydroxyphenylpyruvate dioxygenase. It is used in the treatment of hereditary tyrosinemia type 1 and Alkaptonuria. … It is sold under the brand names Orfadin and Harliku. [L53253, L53258]
Onasemnogene abeparvovec
go.drugbank.com/drugs/DB15528ApprovedInvestigationalOnasemnogene abeparvovec is the first gene therapy that was approved for this indication in the USA. … [Nusinersen] is another gene therapy that is currently approved by the FDA for the treatment of SMA in pediatric and adult patients.
Sulfadoxine
go.drugbank.com/drugs/DB01299ApprovedInvestigationalWithdrawnA long acting sulfonamide that is used, usually in combination with other drugs, for respiratory, urinary tract, and malarial infections.
Efgartigimod alfa
go.drugbank.com/drugs/DB15270ApprovedInvestigationalEfgartigimod alfa for intravenous use was granted FDA approval on December 17, 2021[L39501] and European Commission approval on August 11, 2022 for use in patients with myasthenia gravis. … [A243759,A243784] Efgartigimod alfa is a first-in-class[L39501] antagonist of the neonatal Fc receptor (FcRn) used in the treatment of MG.
Pitavastatin
go.drugbank.com/drugs/DB08860ApprovedInvestigational[A181087, A181406] Pitavastatin and other drugs from the statin class of medications including [atorvastatin], [pravastatin], [rosuvastatin], [fluvastatin], and [lovastatin] are considered first-line … were found in clinical studies to result in a 45.8% to 54.6% decrease in LDL cholesterol levels.
Tividenofusp alfa
go.drugbank.com/drugs/DB17628ApprovedInvestigationalTividenofusp alfa is a first-in-class, brain-penetrant enzyme replacement therapy (ERT) indicated for the treatment of Mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome [L56097, L56099 … Hunter syndrome is a rare, X-linked lysosomal storage disorder caused by a deficiency in the enzyme iduronate-2-sulfatase (IDS), which leads to the toxic accumulation of glycosaminoglycans (GAGs) throughout
Pergolide
go.drugbank.com/drugs/DB01186ApprovedVet approvedWithdrawnWhile the use of pergolide in humans is still approved in only some countries, pergolide is mainly used for veterinary purposes. … The drug was withdrawn from the US market in March 2007 and from the Canadian market in August 2007.